Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofilia a - anti-hemorrágicos - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra pode ser usado em todos os grupos de idade.

Brasile - portoghese - ANVISA (Agência Nacional de Vigilância Sanitária)

produtos roche quÍmicos e farmacÊuticos s.a. - capecitabina - outros antineoplasicos

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - linfoma de células b - agentes antineoplásicos - polivy em combinação com bendamustine e o rituximab é indicado para o tratamento de pacientes adultos com recidivado/refratário difuso de grandes células b linfoma (dlbcl), que não são candidatos a transplante de células tronco hematopoiéticas. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - agentes antineoplásicos - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influenza humana - antivirais para uso sistêmico - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - atrofia muscular, espinhal - outras drogas para distúrbios do sistema músculo-esquelético - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - imunossupressores - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - imune soros e imunoglobulinas, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. veja as seções 4. 4 e 5.

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Unione Europea - portoghese - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - linfoma, folicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.